Research programme: muscular atrophy protein therapeutics - Eleven Biotherapeutics
Latest Information Update: 12 Dec 2012
At a glance
- Originator Eleven Biotherapeutics
- Class Proteins
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Muscular atrophy
Most Recent Events
- 12 Dec 2012 Discontinued - Preclinical for Muscular atrophy in USA (unspecified route)
- 17 Feb 2010 Preclinical trials in Muscle wasting in USA (unspecified route)